Retinal heparanase expression in streptozotocin-induced diabetic rats

Canadian Journal of Ophthalmology

Volumn 45, Issue 1, 2010, Pages 46-51

  Ma, Pingping ^a,b   Luo, Yan ^a   Zhu, Xiaobo ^a   Li, Tao ^a   Hu, Jie ^a   Tang, Shibo ^a  

^a SUN YAT SEN UNIVERSITY   (China)

^b DONGGUAN PEOPLE'S HOSPITAL   (China)

Author keywords

Diabetic retinopathy; Heparanase; Rat; Retina; Vascular endothelial growth factor

Indexed keywords

GLUCOSE; HEPARANASE; PHOSPHOMANNOPENTAOSE SULFATE; SULFATE; UNCLASSIFIED DRUG; VASCULOTROPIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CELL CULTURE; CONTROLLED STUDY; ENDOTHELIUM CELL; ENZYME LINKED IMMUNOSORBENT ASSAY; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; NONHUMAN; PROTEIN EXPRESSION; PROTEIN FOLDING; RAT; RETINA BLOOD VESSEL; STREPTOZOCIN DIABETES; WESTERN BLOTTING;

EID: 76149122193     PISSN: 00084182     EISSN: 17153360     Source Type: Journal    
DOI: 10.3129/i09-200     Document Type: Article

References (38)

1. Moss SE, Klein R, Klein BE. The 14-year incidence of visual loss in a diabetic population. Ophthalmology 1998;105: 998-1003.
2. Grant MB, Afzal A, Spoerri P, Pan H, Shaw LC, Mames RN. The role of growth factors in the pathogenesis of diabetic retinopathy. Expert Opin Investig Drugs 2004;13:1275-93.
3. Qaum T, Xu Q, Joussen AM, et al. VEGF-initiated bloodretinal barrier breakdown in early diabetes. Invest Ophthalmol Vis Sci 2001;42:2408-13.
4. Witmer AN, Vrensen GF, Van Noorden CJ, Schlingemann RO. Vascular endothelial growth factors and angiogenesis in eye disease. Prog Retin Eye Res 2003;22:1-29.
5. Haritoglou C, Kook D, Neubauer A, et al. Intravitreal bevacizumab (Avastin) therapy for persistent diffuse diabetic macular edema. Retina 2006;26:999-1005.
6. Avery RL, Pearlman J, Pieramici DJ, et al. Intravitreal bevacizumab (Avastin) in the treatment of proliferative diabetic retinopathy. Ophthalmology 2006;113:1695.e1-15.
7. Vlodavsky I, Ilan N, Naggi A, Casu B. Heparanase: structure, biological functions, and inhibition by heparin-derived mimetics of heparan sulfate. Curr Pharm Des 2007;13:2057-73.
8. Bame KJ. Heparanases: endoglycosidases that degrade heparan sulfate proteoglycans. Glycobiology 2001;11:91R-8R.
9. Ilan N, Elkin M, Vlodavsky I. Regulation, function and clinical significance of heparanase in cancer metastasis and angiogenesis. Int J Biochem Cell Biol 2006;38:2018-39.
10. Nasser NJ. Heparanase involvement in physiology and disease. Cell Mol Life Sci 2008;65:1706-15.
11. Zcharia E, Zilka R, Yaar A, et al. Heparanase accelerates wound angiogenesis and wound healing in mouse and rat models. FASEB J 2005;19:211-21.
12. Gingis-Velitski S, Ishai-Michaeli R, Vlodavsky I, Ilan N. Antiheparanase monoclonal antibody enhances heparanase enzymatic activity and facilitates wound healing. FASEB J 2007;21: 3986-93.
13. Zcharia E, Metzger S, Chajek-Shaul T, et al. Transgenic expression of mammalian heparanase uncovers physiological functions of heparan sulfate in tissue morphogenesis, vascularization, and feeding behavior. FASEB J 2004;18:252-63.
14. Parish CR, Freeman C, Brown KJ, Francis DJ, Cowden WB. Identification of sulfated oligosaccharide-based inhibitors of tumor growth and metastasis using novel in vitro assays for angiogenesis and heparanase activity. Cancer Res 1999;59: 3433-41.
15. Iversen PO, Sorensen DR, Benestad HB. Inhibitors of angiogenesis selectively reduce the malignant cell load in rodent models of human myeloid leukemias. Leukemia 2002;16: 376-81.
16. Edovitsky E, Elkin M, Zcharia E, Peretz T, Vlodavsky I. Heparanase gene silencing, tumor invasiveness, angiogenesis, and metastasis. J Natl Cancer Inst 2004;96:1219-30.
17. Khachigian LM, Parish CR. Phosphomannopentaose sulfate (PI-88): heparan sulfate mimetic with clinical potential in multiple vascular pathologies. Cardiovasc Drug Rev 2004;22:1-6.
18. Kudchadkar R, Gonzalez R, Lewis KD. PI-88: a novel inhibitor of angiogenesis. Expert Opin Investig Drugs 2008;17:1769-76.
19. Ferro V, Dredge K, Liu L, et al. PI-88 and novel heparan sulfate mimetics inhibit angiogenesis. Semin Thromb Hemost 2007; 33:557-68.
20. Demir M, Iqbal O, Hoppensteadt DA, et al. Anticoagulant and antiprotease profiles of a novel natural heparinomimetic mannopentaose phosphate sulfate (PI-88). Clin Appl Thromb Hemost 2001;7:131-40.
21. Chow LQ, Gustafson DL, O'Bryant CL, et al. A phase I pharmacological and biological study of PI-88 and docetaxel in patients with advanced malignancies. Cancer Chemother Pharmacol 2008;63:65-74.
22. Basche M, Gustafson DL, Holden SN, et al. A phase I biological and pharmacologic study of the heparanase inhibitor PI-88 in patients with advanced solid tumors. Clin Cancer Res 2006;12:5471-80.
23. Rosenthal MA, Rischin D, McArthur G, et al. Treatment with the novel anti-angiogenic agent PI-88 is associated with immune-mediated thrombocytopenia. Ann Oncol 2002;13: 770-6.
24. Lewis KD, Robinson WA, Millward MJ, et al. A phase II study of the heparanase inhibitor PI-88 in patients with advanced melanoma. Invest New Drugs 2008;26:89-94.
25. Li B, Tang SB, Hu J, et al. Protective effects of transcription factor HESR1 on retinal vasculature. Microvasc Res 2006;72: 146-52.
26. Levidiotis V, Freeman C, Punler M, et al. A synthetic heparanase inhibitor reduces proteinuria in passive Heymann nephritis. J Am Soc Nephrol 2004;15: 2882-92.
27. Vlodavsky I, Friedmann Y, Elkin M, et al. Mammalian heparanase: gene cloning, expression and function in tumor progression and metastasis. Nat Med 1999;5:793-802.
28. Fumuso EA, Aguilar J, Giguère S, Rivulgo M, Wade J, Rogan D. Immune parameters in mares resistant and susceptible to persistent post-breeding endometritis: effects of immunomodulation. Vet Immunol Immunopathol 2007;118:30-9.
29. Xavier LL, Viola GG, Ferraz AC, et al. A simple and fast densitometric method for the analysis of tyrosine hydroxylase immunoreactivity in the substantia nigra pars compacta and in the ventral tegmental area. Brain Res Protoc 2005;16:58-64.
30. Vlodavsky I, Korner G, Ishai-Michaeli R, Bashkin P, Bar-Shavit R, Fuks Z. Extracellular matrix-resident growth factors and enzymes: possible involvement in tumor metastasis and angiogenesis. Cancer Metastasis Rev 1990;9:203-26.
31. Fairbanks MB, Mildner AM, Leone JW, et al. Processing of the human heparanase precursor and evidence that the active enzyme is a heterodimer. J Biol Chem 1999;274:29587-90.
32. Edovitsky E, Lerner I, Zcharia E, Peretz T, Vlodavsky I, Elkin M. Role of endothelial heparanase in delayed-type hypersensitivity. Blood 2006;107:3609-16.
33. Chen G, Wang D, Vikramadithyan R, et al. Inflammatory cytokines and fatty acids regulate endothelial cell heparanase expression. Biochemistry 2004;43:4971-7.
34. Maxhimer JB, Somenek M, Rao G, et al. Heparanase-1 gene expression and regulation by high glucose in renal epithelial cells: a potential role in the pathogenesis of proteinuria in diabetic patients. Diabetes 2005;54:2172-8.
35. Han J, Woytowich AE, Mandal AK, Hiebert LM. Heparanase upregulation in high glucose-treated endothelial cells is prevented by insulin and heparin. Exp Biol Med (Maywood) 2007; 232:927-34.
36. ElkinM, IlanN, Ishai-Michaeli R, et al. Heparanase asmediator of angiogenesis: mode of action. FASEB J 2001;15:1661-3.
37. Mikami S, Ohashi K, Katsube K, Nemoto T, Nakajima M, Okada Y. Coexpression of heparanase, basic fibroblast growth factor and vascular endothelial growth factor in human esophageal carcinomas. Pathol Int 2004;54:556-63.
38. Zetser A, Bashenko Y, Edovitsky E, Levy-Adam F, Vlodavsky I, Ilan N. Heparanase induces vascular endothelial growth factor expression: correlation with p38 phosphorylation levels and Src activation. Cancer Res 2006;66:1455-63.